- Home
- PHT vs LRMR Comparison
PHT vs LRMR Comparison
Compare PHT & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHT
- LRMR
- Stock Information
- Founded
- PHT 2002
- LRMR N/A
- Country
- PHT United States
- LRMR United States
- Employees
- PHT N/A
- LRMR N/A
- Industry
- PHT Investment Managers
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- PHT Finance
- LRMR Health Care
- Exchange
- PHT Nasdaq
- LRMR Nasdaq
- Market Cap
- PHT 237.1M
- LRMR 191.4M
- IPO Year
- PHT N/A
- LRMR N/A
- Fundamental
- Price
- PHT $8.13
- LRMR $3.09
- Analyst Decision
- PHT
- LRMR Strong Buy
- Analyst Count
- PHT 0
- LRMR 7
- Target Price
- PHT N/A
- LRMR $17.86
- AVG Volume (30 Days)
- PHT 85.5K
- LRMR 1.4M
- Earning Date
- PHT 01-01-0001
- LRMR 08-06-2025
- Dividend Yield
- PHT 8.76%
- LRMR N/A
- EPS Growth
- PHT N/A
- LRMR N/A
- EPS
- PHT 0.98
- LRMR N/A
- Revenue
- PHT N/A
- LRMR N/A
- Revenue This Year
- PHT N/A
- LRMR N/A
- Revenue Next Year
- PHT N/A
- LRMR N/A
- P/E Ratio
- PHT $7.71
- LRMR N/A
- Revenue Growth
- PHT N/A
- LRMR N/A
- 52 Week Low
- PHT $6.41
- LRMR $1.61
- 52 Week High
- PHT $7.60
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- PHT 68.89
- LRMR 62.04
- Support Level
- PHT $8.05
- LRMR $2.81
- Resistance Level
- PHT $8.05
- LRMR $3.33
- Average True Range (ATR)
- PHT 0.05
- LRMR 0.30
- MACD
- PHT -0.00
- LRMR 0.01
- Stochastic Oscillator
- PHT 90.48
- LRMR 88.29
About PHT Pioneer High Income Fund Inc.
Pioneer High Income Trust is a closed-end management investment company. Its investment objective is to provide a high level of current income and to seek capital appreciation by investing predominantly in below investment grade (high-yield) debt securities, loans, and preferred stocks.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.